BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8639764)

  • 1. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
    Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
    Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.
    Hellström-Lindberg E; Birgegård G; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Merk K; Tangen JM; Winqvist I
    Leuk Lymphoma; 1993 Oct; 11(3-4):221-8. PubMed ID: 7505147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
    Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
    Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.
    Bessho M; Hirashima K; Asano S; Ikeda Y; Ogawa N; Tomonaga M; Toyama K; Nakahata T; Nomura T; Mizoguchi H; Yoshida Y; Niitsu Y; Kohgo Y
    Eur J Haematol; 1997 Apr; 58(4):265-72. PubMed ID: 9186538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
    Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
    Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
    Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
    Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
    Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
    Leuk Res; 1996 Aug; 20(8):693-9. PubMed ID: 8913323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
    Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
    Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
    Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
    Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
    Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
    Miles SA; Mitsuyasu RT; Moreno J; Baldwin G; Alton NK; Souza L; Glaspy JA
    Blood; 1991 May; 77(10):2109-17. PubMed ID: 1709368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential treatment with granulocyte-colony stimulating factor (GCSF) and human recombinant erythropoietin (rH-EPO) in anemia of a patient with myelodysplastic syndrome and high blood transfusion requirements)].
    Borbolla-Escoboza JR; González-Avante CM; López-Hernández MA; Flores-Chapa JD; Collados-Larumbe MT
    Gac Med Mex; 1997; 133(4):355-9. PubMed ID: 9410796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
    Ganser A; Maurer A; Contzen C; Seipelt G; Ottmann OG; Schadeck-Gressel C; Kolbe K; Haas R; Zander C; Reutzel R; Hoelzer D
    Ann Hematol; 1996 Apr; 72(4):237-44. PubMed ID: 8624378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
    Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
    Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.